SPC CHANGES Remicade

摘要

The summary of product characteristics for Remicade(infliximab;Schering-Plough)has been updated to include an additional indication for the treatment of moderate to severe ulcerative colitis in patients who have had an inadequate response to conventional therapy(including corticosteroids and 6-mercaptopurine or azathioprine)or who are intolerant to,or have contraindications for,such therapies.The dose for this indication is 5mg/kg given as an intravenous infusion over two hours followed by additional 5mg/kg infusion doses,two and six weeks after the first infusion,then every eight weeks thereafter.